Cannabis firm sues shipper
Check your travel medical
New orca rescue attempt
No bail in Ottawa killings 
Banks must say rebate 
Regulating power prices
Iran fires at attack drones 
World's largest election 
2 detained in Volkov attack 
Oil and gas leases restricted
Indigo needs turnaround 
Rates slow green economy
Warriors ready for Round 2
Kalamalka Bowl cancelled
Rockets live to fight on
Hilton teams up with Sia
Swift still 'can't forgive' Kim
Grimes to ‘cap the disarray’
Photo: Contributed
Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a deal to sell its Obagi skin care business to a Hong Kong-based group for US$190 million in cash.
The Quebec-based company, headquartered in Laval, estimates its Obagi Medical Products unit will generate about US$85 million of revenue in 2017.
The buyer is a fund managed by a limited partnership that includes China Regenerative Medicine International and Haitong International Securities Group, both headquartered in Hong Kong.
